Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01613014 · ClinicalTrials.gov registry record · Phase 2

ABT-436 for Alcohol Dependence

A Phase 2 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Completed
Registry status
Phase 2
Development phase
150
Enrollment target

NCT01613014 is a Phase 2 study that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01613014, a Phase 2 study, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

COMPLETED
Registry status
Phase 2
Development phase
150 participants
Enrollment target

Study Summary

The primary efficacy endpoint examines the hypothesis that ABT-436 will decrease the weekly percentage of heavy drinking days during Study Weeks 2 through 12 (Days 8-84) as compared to placebo. A "heavy drinking day" is 4 or more drinks per drinking day for women and 5 or more drinks per drinking day for men.

Interventions

  • DRUG ABT-436
  • DRUG Matched Placebo - Sugar Pill

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2013-02
Est. Completion 2015-07
Phase Phase 2

What the Registry Record Tells You About NCT01613014

The ClinicalTrials.gov registry entry for NCT01613014 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which ABT-436 is the first listed.

NCT01613014 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01613014 about?

NCT01613014 is a clinical study titled "ABT-436 for Alcohol Dependence". The primary efficacy endpoint examines the hypothesis that ABT-436 will decrease the weekly percentage of heavy drinking days during Study Weeks 2 through 12 (Days 8-84) as compared to placebo. A "heavy drinking day" is 4 or more drinks per drinking day for women and 5 or more drinks per drinking da...

What is the current status of trial NCT01613014?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2013-02. Estimated completion is 2015-07.

What interventions are being tested in trial NCT01613014?

The interventions under investigation include: ABT-436 (DRUG), Matched Placebo - Sugar Pill (DRUG).

Who is sponsoring clinical trial NCT01613014?

This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.